The role of stavudine in the South African public sector antiretroviral programme: Should the perfect be the enemy of the good?

Southern African Journal of HIV Medicine

Volumn , Issue 23, 2006, Pages

  Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG APPROVAL; DRUG COST; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG USE; FATTY LIVER; GASTROINTESTINAL TOXICITY; HEALTH CARE ACCESS; HEALTH PROGRAM; HELPER CELL; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER FAILURE; LONG TERM CARE; LYMPHOCYTE COUNT; MONOTHERAPY; NEUROPATHY; NEUROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PUBLIC HEALTH; SEPTICEMIA; SOUTH AFRICA; UNITED STATES;

EID: 33748345549     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v7i2.602     Document Type: Article

References (11)

1. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind controlled trial. Bristol-Myers Squibb/019 Study Group. Ann Intern Med 1997; 126(5): 355-363.
2. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START 1). AIDS 2000; 14(11): 1591-1600.
3. Mocroft A, Phillps AN, Lederberber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS 2006; 20(8): 1141-1150.
4. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: Guidelines for a public health approach. World Health Organization. Executive Summary April 2002. Geneva, Switzerland. http://www.who.int/hiv/topics/arv/en/ scaling_exe_summary.pdf (accessed 14 June 2006).
5. Zerit (stavudine) patient information leaflet. Bristol-Myers Squibb. Princeton, NJ 08543, USA http://bms.com (accessed 16 June 2006).
6. Bekker L-G. Myer L, Orrell C, Wood R. A South African community-based antiretroviral programme: Outcomes during 3 years of scale-up. S Afr Med J 2006; 96(4): 315-320.
7. Lawn SD, Myer L, Orrel C, Bekker L-G, Wood R. Early mortality among patients accessing a community-based antiretroviral service in South Africa: Implications for program design. AIDS 2005; 19: 2141-2148.
8. Boule A, Hildebrand K, Coetzee D, et al. Regimen durability and reasons for regimen changes in the first 1 000 treatment naïve adults accessing ART in Kayelitsha. 9th International Workshop on HIV Databases, Budapest, Hungary, 21-22 April 2005.
9. Gallant JE, Staszewski S, Pozniac AL, et al. Efficacy and safety of tenofovir vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292(2): 266-268.
10. Truvada patient information leaflet. http://www.gilead.com/pdf/ truvada_pi/pdf (accessed 16 June 2006).
11. Badri M, Cleary S, Maartens G, et al. When to initiate HAART in sub-Saharan Africa: a cost-effectiveness study. Antivir Ther 2006: 11(1): 63-72.